Digital Scaffolding for a Breakthrough in Parkinson's Therapy

PLEASANTVILLE, N.Y. – June 23, 2026 – In the high-stakes world of biotechnology, the journey from a promising molecule to a patient's bedside is a gantlet of scientific hurdles and financial chasms. For smaller companies, this path is particularly perilous. But a new model is emerging, one where digital architecture provides the critical support structure for biological innovation. This week, clinical-stage biotech firm Right Brain Bio announced its selection into Dassault Systèmes' 3DEXPERIENCE Lab, a move that could significantly accelerate the development of its novel Parkinson's disease therapy, RB-190.

The partnership grants the small Pleasantville-based company access to the MEDIDATA clinical trial platform, an industry-leading suite of tools that could be the digital key to unlocking a faster, more efficient path through the notoriously difficult Phase 2 clinical trials. For the more than 10 million people worldwide living with Parkinson's, this fusion of advanced software and radical science represents a new surge of hope.

The Digital Accelerator: De-Risking the Path to Clinic

For a startup like Right Brain Bio, entering Phase 2 development is like a ship leaving the relative safety of coastal waters for the deep ocean. This stage, designed to test a drug's effectiveness and further evaluate its safety, is where approximately 30% of promising compounds fail. The costs are staggering, with average expenditures for a Phase 2 trial running anywhere from $13 million to over $18 million, and patient recruitment alone can consume a third of the budget.

This is where the collaboration with Dassault Systèmes becomes a game-changer. The French technology giant, known for its virtual twin experiences in industries from aerospace to manufacturing, has made a formidable push into life sciences. Its $5.8 billion acquisition of Medidata Solutions in 2019 brought one of the most powerful clinical trial platforms under its roof. The MEDIDATA platform is a unified, cloud-based system used by 18 of the top 25 pharmaceutical companies to manage everything from data capture and analysis to patient engagement and regulatory compliance.

By joining the 3DEXPERIENCE Lab accelerator, Right Brain Bio gains more than just software; it gains entry into a sophisticated ecosystem. The program is designed to nurture disruptive startups by providing technology, mentorship, and a global network of expertise. For Right Brain Bio, this means leveraging a platform that has been battle-tested in the development of 13 of the top 15 drugs sold in 2018.

"Joining the 3DEXPERIENCE Lab comes at an important time for Right Brain Bio as we prepare for Phase 2 development of RB-190," said Jonathan Sackner-Bernstein, MD, CEO and Founder of RBB. "The combination of Dassault Systèmes' renowned ecosystem and its MEDIDATA clinical trial platform provides development resources to help us execute efficiently, generate high-quality data and position the company for strategic partnerships and future financing. It advances our therapy more rapidly for the growing global population affected by Parkinson's disease."

This access to advanced data management and AI-powered analytics, such as Medidata's new Clinical Data Studio, allows a small team to operate with the efficiency of a much larger organization. It helps streamline trial execution, ensure data integrity, and identify potential safety signals faster, thereby mitigating risk and conserving precious capital.

A Radical Rethink of Parkinson's Pathology

The technology is impressive, but it is the science it supports that holds the potential for a true paradigm shift. For decades, Parkinson's disease has been understood primarily as a disease of dopamine deficiency. The progressive death of dopamine-producing neurons in the brain leads to the characteristic motor symptoms: tremors, stiffness, and slowed movement. The current gold-standard treatment, levodopa, works by converting to dopamine in the brain, temporarily replenishing the supply and alleviating symptoms. However, it does not stop the underlying disease progression, and long-term use often leads to debilitating side effects like dyskinesias.

Right Brain Bio's approach, spearheaded by Dr. Sackner-Bernstein, challenges this foundational concept. Based on a "First Principles-Based Gap Analysis," the company posits that the core problem is not a lack of dopamine, but an excess of toxic, free-floating dopamine inside the neurons themselves. According to this model, when dopamine is not properly sequestered in storage vesicles, it oxidizes and wreaks havoc, leading to mitochondrial dysfunction, the formation of toxic alpha-synuclein clumps, and ultimately, cell death.

The company's lead candidate, RB-190, is designed to address this root cause. It is a repurposed and reformulated version of metyrosine, a small molecule first approved by the FDA in 1979. Metyrosine works by inhibiting tyrosine hydroxylase, the rate-limiting enzyme in dopamine production. The goal is not to eliminate dopamine, but to dial down its synthesis just enough to prevent the toxic intracellular buildup, allowing the neuron's natural housekeeping mechanisms to clear out the damage and restore function.

The preclinical data is compelling. Across nine different animal models of Parkinson's, RB-190 has reportedly demonstrated a reversal of key disease pathologies, including reducing oxidized dopamine and alpha-synuclein deposits while preventing brain cell death. The company's claim that RB-190 could be the first disease-modifying therapy capable of actually reversing motor dysfunction is a bold one, but it is this potential that sets it apart from a field crowded with symptomatic treatments.

The Blueprint for Modern Drug Development

The story of Right Brain Bio and RB-190 is also a case study in a leaner, more strategic approach to drug development. Rather than discovering a new chemical entity from scratch—a process that is incredibly time-consuming and expensive—the company chose to repurpose an existing drug. Metyrosine's long history of clinical use means its safety profile is well-understood, significantly de-risking the development pathway and potentially shortening the timeline to approval.

This pragmatic strategy extends to its operational model. The company, founded in 2018, has remained lean, focusing its resources on the core science and outsourcing key functions through strategic alliances. The partnership with Dassault Systèmes is one pillar of this strategy. Another is the recently announced manufacturing agreement with Suven Pharmaceuticals to produce the high-quality active pharmaceutical ingredient for the upcoming trials.

This network-based approach allows a small, agile team led by an experienced hand like Dr. Sackner-Bernstein—whose career spans clinical practice, FDA regulatory oversight, and even engagement with DARPA—to punch far above its weight. It's a model that leverages external expertise and infrastructure to navigate the capital-intensive phases of drug development, a necessary evolution in an industry where innovation must also be sustainable.

As Right Brain Bio prepares to submit its Investigational New Drug (IND) application and launch its Phase 2 trial in 2025, the stakes are immense. The global prevalence of Parkinson's has doubled in the last 25 years, and without a breakthrough, the number of cases is projected to continue its steep climb. The partnership with Dassault Systèmes provides the digital tools to run a faster, smarter trial. If the data from that trial validates the radical science behind RB-190, it could not only redefine the treatment of Parkinson's disease but also provide a powerful new blueprint for how technology and biology can converge to solve medicine's most intractable problems.